Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 01/11/19 at 01:14pm

Happy Friday! It's been a fast-moving week as always, though unusually one characterised by trial failures, but the most popular stories this week ranged from contamination fears with Mylan's household-name anxiety drug Xanax and the UKRI and BBSRC's cash injection to cultivate pharma and biotech PhDs in the UK.

However, the biggest story was the news that the FDA has temporarily frozen a study into the global bestseller Humira over concerns with the findings.

10. AstraZeneca's Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy in treatment-naïve metastatic non-small cell lung cancer (NSCLC), showing that the therapy met its primary endpoint in the trial.

9. GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients

Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the efficacy of the company’s M72/AS01E tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection.

8. European approval announced for Astellas' Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for the treatment of relapsed or refractory (resistant to treatment) acute myeloid leukaemia (AML) in adult patients whose tumour exhibits a FLT3 mutation (FLT3mut+).

7. Bavencio+Inlyta combo OK'd in Europe for first-line advanced kidney cancer

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), it has emerged.

6. Biogen plans Alzheimer’s drug approval after initial research failure

Biogen is planning to seek approval for its experimental drug aducanumab, that could potentially be first to treat Alzheimer’s and be the first drug to be approved since 2003.

5. Seattle Genetics reports topline phase 3 HER2-Positive Breast Cancer Data

Seattle Genetics, a strong competitor in the breast cancer space, has reported topline results in its phase 3 study evaluating tucatinib as an adjunctive therapy to Roche’s Herceptin (trastuzumab) plus capecitabine against Herceptin and capecitabine in third-line HER2- positive breast cancer patients.

4. European Commission approves Sanofi's Dupixent in chronic rhinosinusitis with nasal polyposis

Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged.

3. Mylan issues recall for anxiety drug Xanax over contamination fears

Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be contaminated with a “foreign substance” and pose a risk to patients.

2. UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships

The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of £170 million to three key UK universities following a successful bid.

1. FDA slams brakes on trial for world's most expensive drug following safety concerns in children

The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million – after safety concerns were raised during study in animals.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches